Skip to Content

Ga 68 PSMA-11 FDA Approval History

FDA Approved: Yes (First approved December 1, 2020)
Brand name: Ga 68 PSMA-11
Dosage form: Injection
Company: University of California, San Francisco
Treatment for: Diagnosis and Investigation

Ga 68 PSMA-11 Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer.

Development Timeline for Ga 68 PSMA-11

DateArticle
Dec  1, 2020ApprovalFDA Approves Gallium 68 PSMA-11 as the First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.